Journal
JOURNAL OF THORACIC DISEASE
Volume 10, Issue 5, Pages 3102-3118Publisher
AME PUBL CO
DOI: 10.21037/jtd.2018.05.11
Keywords
Drug-resistant tuberculosis (drug-resistant TB); HIV co-infection; bedaquiline; linezolid; delamanid
Categories
Ask authors/readers for more resources
Tuberculosis (TB) remains a major problem globally, and is the leading cause of death from an infectious agent. Drug-resistant TB threatens to marginalise the substantial gains that have recently been made in the fight against TB. Drug-resistant TB has significant associated morbidity and a high mortality, with only half of all multidrug-resistant TB patients achieving a successful treatment outcome. Patients with drug-resistant TB in resource-poor settings are now gaining access to newer and repurposed anti-TB drugs such as bedaquiline, delamanid and linezolid. However, with ever increasing rates of co-morbidity, there is little guidance on how to manage complex patients with drug-resistant TB. We address that knowledge gap, and outline principles underpinning the management of drug-resistant TB in special situations including HIV co-infection, pregnancy, renal disease, liver disease, diabetes, and in the critically ill.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available